Cantargia - Full Phase I data presented at ASCO
Cantargia presented full data (n=22) from the Phase I part of the CANFOUR study at ASCO on 2 June 2019. These data (safety, biomarker and early efficacy data) were consistent with the interim data presented previously and so did not have an impact on the share price. The recent directed share issue (March 2019) raised SEK106m (gross) primarily from long-term institutional investors. This will fund the Phase IIa part of the CANFOUR study, expansion of the most promising subgroup, initiation of a new US study and efficacy study preparations. Our valuation is slightly higher at SEK2.62bn, but lower on a per share basis at SEK36.0/share.Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.